Clinical trials: Vitamin K 2
Deep Venous Thromboembolism
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
Oral warfarin anticogulation for the prevention and treatment of patients with venous thromboembolism is one of the most used therapies in clinical practice.
- Trial name
- NCT00247702
- Testing
- warfarin
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Deep-Vein Thrombosis
Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or…
- Trial name
- NCT00252005
- Testing
- Apixaban
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 520 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification
Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of cardiovascular events. The development of arterial calcification results from imbalance between calcification promoting and inhibiting…
- Trial name
- VitaK-CAC (NCT01002157)
- Testing
- Menaquinone-7 (Vitamin K2)
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Maastricht University Medical Center
Endothelial Dysfunction, Hyperhomocysteinemia
Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function
The effect of a combination product (Verum ) with L-arginine, Pycnogenol, vitamin K2, R-(+)-alpha-lipoic acid and vitamins B6, B12 and folic acid is investigated in a double blind placebo-controlled cross-over study.
- Conditions
- Endothelial Dysfunction, Hyperhomocysteinemia, Hypertension Grade I, Subgroup "Borderline" (WHO)
- Trial name
- NCT02392767
- Testing
- Verum
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dr. Loges & Co. GmbH
Atrial Fibrillation (AF)
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to…
- Trial name
- PACIFIC-AF (NCT04218266)
- Testing
- BAY2433334, Apixaban
- Where
- 93 sites in Austria, Belgium and 12 more
- Volunteers
- 755 people
- Sponsor
- Bayer
Migraine Headache, Arterial Stiffness
Vitamin K2 Supplementation in Adult Episodic Migraine
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women.
- Conditions
- Migraine Headache, Arterial Stiffness, Vitamin K Deficiency
- Trial name
- ViKEM (NCT05943457)
- Testing
- Vitamin K2 or menaquinone-7
- Where
- Lebanon
- Volunteers
- 160 people
- Sponsor
- Sola Aoun Bahous, M.D. Ph.D.
Aortic Valve Disease
Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)
Aortic Stenosis is a common but fatal disease when it becomes symptomatic, specially if not treated. Until now surgery remains the only reliable and effective treatment.
- Trial name
- DECAV-K2 (NCT03305536)
- Testing
- Vitamin K2 (Menaquinone 7) + Vitamin D3
- Where
- Lebanon
- Volunteers
- 150 people
- Sponsor
- Hopital St. Georges, Ajaltoun
Coronary Artery Disease
The DANish COronary DEcalcification (DANCODE) Trial
1. Abstract Introduction Coronary artery calcification (CAC) and especially progression in CAC is a strong predictor of acute myocardial infarction and cardiovascular mortality.
- Trial name
- DANCODE (NCT05500443)
- Testing
- Vitamin K2 (Menaquinone-7)
- Where
- 3 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Odense University Hospital
Atrial Fibrillation, Venous Thromboses
Pharmacogenetic Dosage Algorithm for Acenocoumarol
The use of coumarins has been a challenge for doctors because of its narrow therapeutic range and they show great inter and intra-individual variability in the dose necessary to achieve an international normalized ratio (INR)…
- Conditions
- Atrial Fibrillation, Venous Thromboses, Cardiac Valve Disease
- Trial name
- NCT03015025
- Testing
- Acenocoumarol
- Where
- Spain
- Volunteers
- 340 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz